Today: 17 January 2026
Subscribe
Browse Category

Medical Technology News 3 November 2025 - 7 December 2025

Intuitive Surgical (ISRG) Stock on December 7, 2025: Earnings Beat, Da Vinci 5 Momentum and What Wall Street Expects Next

Intuitive Surgical (ISRG) Stock on December 7, 2025: Earnings Beat, Da Vinci 5 Momentum and What Wall Street Expects Next

Intuitive Surgical stock today: where things stand Intuitive Surgical Inc. (NASDAQ: ISRG), the robotics and minimally invasive surgery leader behind the da Vinci and Ion platforms, continues to trade near the top of its 52‑week range as of December 7, 2025. Specialist services that track Intuitive Surgical’s price history also show a strong rebound over the last three months, with…
7 December 2025
····
Medtronic PLC (MDT) Stock Outlook December 7, 2025: Price, Dividend, Hugo Robot FDA Win and 2026 Forecast

Medtronic PLC (MDT) Stock Outlook December 7, 2025: Price, Dividend, Hugo Robot FDA Win and 2026 Forecast

Updated: December 7, 2025 Key Takeaways 1. Medtronic (MDT) Stock Snapshot on December 7, 2025 As of the latest completed trading session (Dec. 5, 2025), Medtronic’s NYSE‑listed shares closed at $101.36, with modest after‑hours trading around $101.31. StockAnalysis Key stats at a glance: Trading over the last week has been choppy as markets digest macro headlines and rotations within healthcare.…
7 December 2025
···
Medtronic (MDT) Stock News Today: Hugo Robot FDA Clearance, Diabetes Spin-Off and Dividend Strength Shape 2026 Outlook

Medtronic (MDT) Stock News Today: Hugo Robot FDA Clearance, Diabetes Spin-Off and Dividend Strength Shape 2026 Outlook

As of the close on 5 December 2025, Medtronic plc (NYSE: MDT) stock trades around $101.36–$101.39 per share, giving the medical device giant a market capitalization of roughly $130 billion, a P/E ratio near 27.4, and a dividend yield of about 2.8%. MarketBeat In the first week of December, Medtronic has delivered a flurry of stock‑moving news: a new FDA…
6 December 2025
····
Intuitive Surgical (ISRG) Stock in December 2025: Earnings Beat, Tariff Risks and New Robotic Rivals

Intuitive Surgical (ISRG) Stock in December 2025: Earnings Beat, Tariff Risks and New Robotic Rivals

Published: December 6, 2025 Intuitive Surgical, Inc. (NASDAQ: ISRG), the pioneer of robotic-assisted surgery and maker of the da Vinci and Ion systems, remains one of the most closely watched healthcare stocks as 2025 draws to a close. The company has delivered a powerful third-quarter earnings beat, continued double‑digit procedure growth and new AI-driven product upgrades—while at the same time…
6 December 2025
···
Picard Medical (PMI) Stock Soars 82% After Artificial Heart Breakthrough: Is This Rally Sustainable?

Picard Medical (PMI) Stock Soars 82% After Artificial Heart Breakthrough: Is This Rally Sustainable?

Picard Medical, Inc. (NYSE American: PMI) just staged one of the most dramatic moves on Wall Street, with its stock surging more than 80% on December 4, 2025, after the company released new data on its next‑generation artificial heart. Investors are now asking a simple question: is this the start of a longer rerating, or just another spike in a…
5 December 2025
····
Medtronic (MDT) Stock Near 52‑Week High as Truist Hikes Target and Norges Bank Buys Big

Medtronic (MDT) Stock Near 52‑Week High as Truist Hikes Target and Norges Bank Buys Big

Medtronic plc (NYSE: MDT) is back in the spotlight on 29 November 2025, with its stock trading close to record levels after a strong earnings beat, a fresh wave of analyst updates and sizeable moves from some of the world’s biggest institutional investors. Below is a deep dive into what’s moving Medtronic stock today, and what it could mean for…
30 November 2025
····
Abbott Laboratories (ABT) Stock Today, November 26, 2025: Insider Sale, $21B Exact Sciences Deal and Libre 3 Sensor Correction in Focus

Abbott Laboratories (ABT) Stock Today, November 26, 2025: Insider Sale, $21B Exact Sciences Deal and Libre 3 Sensor Correction in Focus

Abbott Laboratories (NYSE: ABT) enters Wednesday, November 26, 2025 with its share price hovering around $128 after a modest gain in Tuesday’s session. Investors are weighing three main storylines: a fresh insider stock sale, the $21 billion takeover of Exact Sciences, and a safety correction affecting millions of Libre 3 glucose sensors, all against the backdrop of solid earnings and…
26 November 2025
····
Abbott Laboratories (ABT) to Buy Exact Sciences in Up to $23 Billion Cancer Diagnostics Deal – All the Key News on November 20, 2025

Abbott Laboratories (ABT) to Buy Exact Sciences in Up to $23 Billion Cancer Diagnostics Deal – All the Key News on November 20, 2025

Abbott Laboratories (NYSE: ABT) shook the healthcare and medtech markets today, November 20, 2025, by announcing a definitive agreement to acquire cancer diagnostics specialist Exact Sciences Corporation (NASDAQ: EXAS) in an all‑cash transaction valuing the target at about $21 billion in equity and roughly $23 billion including debt. Reuters The move marks Abbott’s largest acquisition in nearly a decade and…
20 November 2025
····
Abbott to Acquire Exact Sciences for $21 Billion in Cancer Screening Mega-Deal

Abbott to Acquire Exact Sciences for $21 Billion in Cancer Screening Mega-Deal

Abbott has agreed to acquire cancer diagnostics specialist Exact Sciences in a cash deal valued at about $21 billion in equity, or roughly $23 billion including debt, in one of the biggest healthcare transactions of 2025 and Abbott’s largest deal in nearly a decade. Abbott MediaRoom The transaction gives Abbott an immediate leadership position in fast‑growing cancer screening and precision…
20 November 2025
····
Abbott (ABT) Stock Slides on Mixed Q3 Results – Is a Rally Over?

Abbott Nears Takeover of Exact Sciences, Sending Cancer Test Maker’s Stock Soaring on November 19, 2025

Abbott Laboratories is in advanced talks to acquire cancer diagnostics specialist Exact Sciences, in what could be the healthcare giant’s largest deal in nearly a decade and a major shake-up for the global cancer testing market. Bloomberg Abbott in Talks for Biggest Deal in Nearly a Decade On Wednesday, November 19, 2025, multiple outlets reported that Abbott Laboratories is close…
19 November 2025
····
Boston Scientific Stock Rockets on Blowout Q3 Results and Major Medical Wins

Boston Scientific (BSX) Stock Today: Price Slips as Neuromodulation Bull Case, Epic EHR Deal and Big Fund Moves Shape the Outlook – November 19, 2025

Boston Scientific Corporation (NYSE: BSX) shares traded lower on Wednesday, November 19, 2025, even as a wave of fresh research, strategic partnership news and institutional ownership updates painted a largely constructive long‑term picture for the medtech giant. BSX stock price on 19 November 2025 As of late Wednesday trading, Boston Scientific stock was changing hands at around $96.6, down roughly…
19 November 2025
···
ClearPoint Neuro (CLPT) Stock Skyrockets on Brain Therapy Breakthroughs – 2025 Deep Dive

ClearPoint Neuro (CLPT) Stock Skyrockets on Brain Therapy Breakthroughs – 2025 Deep Dive

Stock Performance & Trading Trends (2025) ClearPoint Neuro’s stock has delivered dramatic gains in 2025, transforming from a little-known small-cap into a high-flyer. The share price rallied over 300% from 2024 lows, driven by positive news in both the company’s own product line and its partners’ clinical trial successes. Notably, CLPT climbed from roughly $5.50 in May 2024 to over…
3 November 2025
··
1 2 3 4

Stock Market Today

  • Moog (MOG.A) Valuation Appears Fair After DCF Check, But Upside Limited
    January 17, 2026, 2:06 PM EST. Moog Inc. trades near $291 after a strong multi-year run, with 6.7% weekly, 19.3% over 30 days, and 292.9% over five years. A Simply Wall St valuation pack gives Moog a 3/6 value score, reflecting mixed signals from different methods. A 2-stage Discounted Cash Flow (DCF) model pegs intrinsic value at about $299.78 per share, versus the $290.80 close, implying roughly a 3% discount and a fair value stance. The model uses Free Cash Flow to Equity (FCFE), with trailing FCF around $103.6 million and forecasts to 2027 of $273.8 million; projections extend to 2035. P/E remains a quick lens on price vs. earnings, but growth and risk shift the balance. In short, Moog looks fairly valued, but near-term catalysts matter.
Go toTop